AbbVie (ABBV) Files for Skyrizi to Treat Crohn's Disease in EU

Published on December 1, 2021

AbbVie (ABBV) submits a regulatory application in the European Union, seeking approval for risankizumab (Skyrizi) for the treatment of Crohn's disease.

Continue reading on website
Other news

Airline Stock Roundup: Omicron-Related Updates Grab Headlines, RYAAY in Focus

December 1, 2021
Delta (DAL) and United Airlines (UAL) decide not to change their schedule to South Africa.

How to Stop Imposter Syndrome From Killing Your Drive

December 1, 2021
Imposter Syndrome affects us all, but as an entrepreneur, your ability to manage it can make or break your business.